BusinessAbeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIABy Nasdaq OMXFeb 8, 2018, 7:00 PM UTC
BusinessAbeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical TrialBy Nasdaq OMXFeb 7, 2018, 1:45 PM UTC
BusinessAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis BullosaBy Nasdaq OMXJan 29, 2018, 1:45 PM UTC
BusinessAbeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXNov 15, 2017, 1:25 PM UTC
BusinessAbeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, OhioBy Nasdaq OMXOct 4, 2017, 12:45 PM UTC
BusinessAbeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical OfficerBy Nasdaq OMXJul 25, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy ProgramBy Nasdaq OMXJun 29, 2017, 12:15 PM UTC
BusinessABEO LOSS NOTICE: Rosen Law Firm Reminds Abeona Therapeutics Inc. Investors of Important Feb. 14 Deadline in Class Action - ABEOBy Nasdaq OMXJan 25, 2017, 12:57 AM UTC
